Evidence map›Paper›PMID 37504336›Full record

ArticleCurrent oncology (Toronto, Ont.)2023

Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC.

Parneet K Cheema, Shantanu O Banerji, Normand Blais, Quincy S-C Chu, Rosalyn A Juergens, Natasha B Leighl, Adrian Sacher, Brandon S Sheffield, Stephanie Snow, Mark Vincent and 3 more

Open access · goldAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Therapeutic advances with KRASCancer gene therapy · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 11 institutions in 1 country.

Parneet K CheemaDivision of Medical Oncology, William Osler Health System, University of Toronto, Brampton, ON L6R 3J7, Canada.
Shantanu O BanerjiCancerCare Manitoba Research Institute, Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 0V9, Canada.ORCID 0000-0002-7531-1378
Normand BlaisDepartment of Medicine, Centre Hospitalier de l'Université de Montréal, University of Montreal, Montreal, QC H2X 3E4, Canada.ORCID 0000-0003-2698-4362
Quincy S-C ChuDivision of Medical Oncology, Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada.
Rosalyn A JuergensDepartment of Medical Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, ON L8V 5C2, Canada.
Natasha B LeighlDepartment of Medicine, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5S 1A8, Canada.
Adrian SacherDepartment of Medicine, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5S 1A8, Canada.
Brandon S SheffieldDepartment of Laboratory Medicine, William Osler Health System, Brampton, ON L6R 3J7, Canada.
Stephanie SnowDivision of Medical Oncology, Department of Medicine, QEII Health Sciences Centre, Dalhousie University, Halifax, NS B3H 2Y9, Canada.ORCID 0000-0003-3847-0289
Mark VincentDepartment of Medical Oncology, London Regional Cancer Program, London, ON N6A 5W9, Canada.
Paul F Wheatley-PriceDepartment of Medicine, The Ottawa Hospital Research Institute, The Ottawa Hospital, University of Ottawa, Ottawa, ON K1H 8L6, Canada.
Stephen YipBC Cancer, Vancouver, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.ORCID 0000-0002-8514-9861
Barbara L MeloskyDepartment of Medical Oncology, BC Cancer-Vancouver Centre, Vancouver, BC V5Z 4E6, Canada.ORCID 0000-0003-2865-659X
University Health Network · CACancerCare Manitoba · CACancer Care Ontario · CACentre Hospitalier de l’Université de Montréal · CADalhousie University · CAJuravinski Cancer Centre · CAUniversity of Alberta · CAUniversity of British Columbia · CAUniversity of Ottawa · CAUniversity of Toronto · CAWilliam Osler Health System · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Activating mutations in

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsCanadaConsensusHumansProto-Oncogene Proteins p21(ras)KRAS protein, humanProto-Oncogene Proteins p21(ras)immune checkpoint inhibitorsKRAS G12Cmutation testingNSCLCresistancetargeted therapy

Identifiers

PMID37504336
PMCPMC10377814
OpenAlexW4383552633

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.